ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2485

Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs

Damemarie Paul1, Laura McDonald1, Alexander Marshall2, Tammy Curtice3, Melissa Lingohr-Smith4, Brandy Menges4 and Jay Lin4, 1Bristol-Myers Squibb, Lawrenceville, NJ, 2HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, 3Bristol-Myers Squibb, Princeton, NJ, 4Novosys Health, Green Brook, NJ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Abatacept, infection and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis (RA) patients. The potential cost differences associated with the reduced risk of infection among RA patients treated with abatacept vs. other tDMARDs is not well understood. We therefore compared infection-related hospitalization risk and associated costs of RA patients experienced with a tumor necrosis factor-α inhibitor (TNFi) who subsequently received abatacept vs. other tDMARDs, including another TNFi or other non-TNF-α inhibitor (non-TNFi).

Methods: Patients initiating a tDMARD (index drug/date) who had ≥1 inpatient diagnosis or ≥2 outpatient diagnoses of RA in the 12 months prior to the index date were identified in MarketScan data (1/1/2010-3/31/2016). Patients were required to have been previously treated with a TNFi and have 12 months of insurance coverage prior to the index date (baseline period) and throughout the follow-up period (≥12 months; up to 36). Unadjusted and multivariable adjusted regression were used to evaluate the impact of the index drug on infection-related hospitalizations and the per-patient per-month (PPPM) associated costs. Log transformation and gamma distribution were used in the regression analysis of cost data where cost values plus $1 were used so that the after the log transformation the original cost data of $0 will have the value of log(1)=0.

Results: Of the study population, 308 patients (mean age: 55 years; 86% female) were treated with abatacept, 1,032 with a TNFi (mean age: 52 years; 82% female), and 321 with another non-TNFi (mean age: 55 years; 76% female). Compared to the baseline period, the proportion of patients with infection-related hospitalizations declined in the follow-up period, as did infection-related hospitalization cost among patients treated with abatacept, while increasing in the follow-up period for both the TNFi and non-TNFi cohorts (Table). After adjusting for differences in patient characteristics, Cox regression analysis showed that the risk for an infection-related hospitalization was significantly greater for RA patients treated with a TNFi vs. abatacept (HR: 2.6; 95% CI: 1.2-5.8, P=0.02) and numerically higher for those treated with another non-TNFi vs. abatacept (HR: 1.9; CI: 0.7-4.7, P=0.19). The change in infection-related hospitalization cost PPPM was significantly higher for RA patients treated with a TNFi vs. patients treated with abatacept ($73; 95% CI: $16-$201, P=0.006); and was numerically higher but not statistically significant for patients treated with another non-TNFi ($66; 95% CI: -$8-$211, P=0.08).

Conclusion: In the real-world setting in the US, patients treated with abatacept vs. a TNFi had a lower risk for infection-related hospitalization and lower associated hospitalization cost.


Disclosure: D. Paul, Bristol-Myers Squibb, 3; L. McDonald, Bristol-Myers Squibb, 3; A. Marshall, Bristol-Myers Squibb, 3; T. Curtice, Bristol-Myers Squibb, 1, 3; M. Lingohr-Smith, Novosys Health, 3; B. Menges, Novosys Health, 3; J. Lin, Novosys Health, 3,Bristol-Myers Squibb, 5.

To cite this abstract in AMA style:

Paul D, McDonald L, Marshall A, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparison-of-risk-for-infection-related-hospitalization-and-associated-costs-of-biologic-experienced-rheumatoid-arthritis-patients-treated-with-abatacept-versus-other-targeted-disease-modifying-antir/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-risk-for-infection-related-hospitalization-and-associated-costs-of-biologic-experienced-rheumatoid-arthritis-patients-treated-with-abatacept-versus-other-targeted-disease-modifying-antir/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology